Cervical cancer is a malignancy arising in the cervix, often linked to persistent high-risk HPV infection. It remains an important global women's health cancer with preventable burden through vaccination and screening.
Clinical trials show a pancreatic cancer drug nearly doubles survival, a head-and-neck therapy shrinks tumors, and new research explains drug resistance. Cancer mortality is falling in the US and UK.
Two novel cervical cancer treatment approaches show progress: the CRAIN trial has completed dose-finding for tolinapant, an apoptosis inhibitor, while ICMR develops the SHetA2 pill for precancerous lesions.
The European Medicines Agency is enforcing clinical trial transparency and has launched a new vaccine information initiative, while a coalition of health professionals warns of suboptimal vaccination coverage across Europe. An analysis also shows that only a portion of EMA-approved medicines are available to NHS patients in England after additional assessments.
Two studies published in Nature Medicine and Military Medical Research link accelerated biological aging in younger generations to rising rates of early-onset cancers. Researchers found that people born in more recent decades show larger gaps between their chronological and biological ages, with stronger risks for lung, gastrointestinal, and uterine cancers. A separate global analysis identified six cancers now rising faster in younger adults than older populations.
The FDA has cleared CStone Pharmaceuticals' investigational new drug application to begin a Phase II trial of its trispecific antibody CS2009 in advanced solid tumors. The multicenter trial will evaluate monotherapy and combination regimens across nine cancer types in Australia, China, and the U.S. Initial Phase I data showed a favorable safety profile and encouraging antitumor activity.
Twenty years after HPV vaccine approval, head and neck cancers have become the most common HPV-related cancer with 16,000 cases annually. The incidence tripled from 2000 to 2017, primarily affecting men in their 40s to 60s. Vaccination rates among teens reached approximately 77-79% for at least one dose in 2024.
The NHS-Galleri trial of the Galleri multi-cancer early detection test did not meet its primary endpoint of reducing combined Stage III-IV cancers. Secondary results showed a 26% reduction in Stage IV diagnoses by the third screening round for 12 deadly cancers. The test increased cancer detection rates four-fold compared to standard screening alone.
Three-time cervical cancer survivor Samantha Gonzales-Russell urges patients to trust their instincts, seek second opinions and advocate for themselves. She emphasizes that persistent symptoms like abnormal bleeding or pain should never be dismissed, and that mental health support should be part of cancer care from the start.
Cancer care is being transformed by targeted therapy, immunotherapy, personalized medicine, and emerging mRNA-based universal cancer vaccines. Advances in immunotherapeutics and cellular therapies are improving survival rates, while an off-the-shelf mRNA vaccine from the University of Florida is already in human trials.
The FDA has cleared the Onclarity HPV Self-Collection Kit for at-home use, with availability by prescription expected in the coming months. A JAMA Network Open study found 61% of women still prefer clinic screening, while 20% prefer self-sampling at home.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07777094 |
TS Triage of HR-HPV Positive Population and Its Accuracy Study |
ACTIVE_NOT_RECRUITING | |
| NCT07770100 |
Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07768358 |
Tucatinib Continuation Study |
NOT_YET_RECRUITING | PHASE4 |
| NCT07702721 |
Intraoperative Microscopic Assessment of Lymph Node Status in Gynecological Malignancies |
NOT_YET_RECRUITING | |
| NCT07696169 |
Disease Evolution and Risk Factors of AIDS-related Prevalent Cancers |
NOT_YET_RECRUITING | |
| NCT07676461 |
Oral, Fecal and Intratumoral Microbiome Atlas in Colombian Patients With Advanced Solid Tumors Receiving First-Line Immunotherapy |
RECRUITING | |
| NCT07673211 |
Circulating cfDNA and HPV as Prognostic Biomarkers for First-Line Recurrent Metastatic Cervical Cancer |
NOT_YET_RECRUITING | |
| NCT07668284 |
COQ10 and Vitamin E for Off-Target Radiation Toxicity |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07663006 |
Breast and Cervical Cancer Stigma in Rwanda |
NOT_YET_RECRUITING | NA |
| NCT07649174 |
Cadonilimab Plus Chemotherapy in LACC: A Prospective, Multicenter, Randomized Phase II Trial |
NOT_YET_RECRUITING | PHASE2 |
